DNA Synthesis Market Trends: How Synthetic Biology Is Transforming Biotechnology Research
Chemical and Enzymatic Pathways Shaping the DNA Synthesis
Market
Custom DNA has become a basic input for biopharma,
diagnostics and research laboratories, and how it is produced matters as much
as how much is needed. According to Polaris Market Research, the
DNA synthesis market was valued at USD 4.26 billion in 2025, with a 2026
estimate of USD 4.96 billion and a projection of USD 17.24 billion by 2034,
reflecting a CAGR of 16.85% from 2026 to 2034. This article focuses on the
production technologies behind those figures and what they mean for B2B buyers
choosing suppliers and workflows.
Oligonucleotide Synthesis Anchors the Product Mix
By type, the report divides the industry into oligonucleotide
synthesis and gene synthesis. Oligonucleotide synthesis held
a 68.9% share in 2025, driven by uses such as PCR and next-generation
sequencing. For laboratories running routine amplification and sequencing
workflows, short custom oligonucleotides remain the everyday requirement, which
is why oligonucleotide synthesis sits at the center of most supplier
offerings. The page expects gene synthesis to grow at the highest rate
over the forecast period, while biopharma expansion is driving demand for gene
constructs, antibody libraries and synthetic vaccines. The report also segments
the industry by application, covering diagnostics, therapeutics, and research
and development.
Chemical and Enzymatic Production Compared
Polaris compares the two main production routes. Chemical
DNA synthesis uses phosphoramidite chemistry and is well established,
suited to short and medium oligonucleotides. Its accuracy declines as sequences
get longer, and it generates significant chemical waste. Enzymatic DNA
synthesis uses enzymes under biological conditions, is potentially faster,
offers higher fidelity for long sequences and is more environmentally friendly.
Its costs are expected to fall as the technology matures, although the page
still describes it as emerging but gaining traction.
For procurement teams, the practical takeaway is that chemical
DNA synthesis remains the proven route for shorter sequences, while enzymatic
DNA synthesis deserves evaluation wherever long, high-fidelity sequences
matter. An October 2025 development cited on the page, an enzymatic platform
with an On-Time Guarantee that delivers sequence-perfect clonal DNA up to 50
kb, shows how suppliers are positioning around that need.
Restraints Buyers Should Weigh
The report lists several challenges: the high cost of long
sequences, error rates that rise with sequence length, regulatory complexity
across regions, scalability limitations, and technical complexity with
specialized requirements. High R&D costs also appear in the table of
contents. Buyers should weigh these constraints against the sequence lengths
and volumes their programs actually require, and compare how each supplier
addresses accuracy as constructs grow longer.
𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞
𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
https://www.polarismarketresearch.com/industry-analysis/dna-synthesis-market
Automation and AI in Design Workflows
Polaris identifies the integration of automation and AI into
DNA synthesis workflows as an opportunity. According to the page, AI can
optimize synthesis based on protocol, sequence complexity and reagent analysis,
enable adaptive control of temperature, timing and reagent flow, and identify
failures, reagent degradation and contamination to reduce waste. It also
supports automated sequence design. In the area of synthetic DNA design,
the page cites an October 2024 example in which the CODA platform designed
synthetic DNA components with high accuracy. Teams building design-to-order
pipelines should ask suppliers how their synthetic DNA design tools
connect to the synthesis workflow itself.
Questions to Ask Before Choosing a Supplier
Three questions can structure supplier conversations. First,
how long are the sequences a program needs, given that chemical accuracy
declines with length while enzymatic approaches offer higher fidelity for long
sequences? Second, how does the supplier handle error rates and scalability,
both of which the report lists among its challenges? Third, how well do its
automation and AI features fit existing workflows? The answers will show
whether a partner suits short, routine orders or more demanding long-sequence
work.
Regional and Competitive Context
North America was the largest region in 2025 with a 42.4%
share, and the US is projected to grow at a CAGR of 17.1% from 2026 to 2034.
Asia Pacific is projected to grow at a CAGR of 17.6%, driven in part by
genomics and vaccines, while India is projected at 17.5%. In March 2025, IDT
partnered with Elegen to offer early access to its ENFINIA Plasmid DNA service
for genes of 5-15 kb, a development relevant to buyers of gene synthesis.
Polaris lists 15 key players: BIONEER CORPORATION; Camena
Bioscience Ltd.; DNA Script SAS; Eton Bioscience, Inc.; Eurofins Scientific SE;
GenScript Biotech Corporation; IBA Lifesciences GmbH; Integrated DNA
Technologies, Inc.; LGC Biosearch Technologies Limited; Molecular Assemblies,
Inc.; Quintara Biosciences, Inc.; Synbio Technologies, Inc.; Thermo Fisher
Scientific, Inc.; Touchlight Genetics Ltd.; and Twist Bioscience Corporation.
Its Porter's Five Forces ratings are moderate for supplier power, low for the
threat of new entrants, moderate for buyer power and for the threat of
substitutes, and high for rivalry among existing firms.
Conclusion
The production route a supplier uses shapes what a buyer can
order. Established chemistry remains well suited to shorter sequences,
enzymatic approaches are gaining traction for longer ones, and AI-assisted
workflows are emerging as an opportunity. Buyers should match technology to
their sequence requirements and weigh cost, error rates and regulatory
complexity before selecting a partner in the fast-growing
DNA synthesis market.
More Trending Latest Reports By Polaris Market Research:
Carbon
Footprint Management Market
Healthcare
Interoperability Solutions Market
Comments
Post a Comment